AZD 2820

Drug Profile

AZD 2820

Alternative Names: AZD-2820

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Palatin Technologies
  • Developer AstraZeneca
  • Class Obesity therapies; Peptides
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 29 Sep 2015 Palatin terminates its research collaboration and license agreement with AstraZeneca for melanocortin 4 receptor agonists in USA
  • 07 Sep 2012 Discontinued - Phase-I for Obesity in United Kingdom (SC)
  • 20 Jun 2012 AstraZeneca terminates phase I trial in Obesity in UK (NCT01469923)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top